Troglitazone 5 mg | 99.36%
TargetMol

Troglitazone is a PPARγ agonist with anti-inflammatory and anti-tumor activity.
More Information Supplier PageTroglitazone is a PPARγ agonist with anti-inflammatory and anti-tumor activity.
More Information Supplier PageMN-64 is a tankyrases inhibitor, showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and Wnt signaling inhibition.
More Information Supplier PageMN-64 is a tankyrases inhibitor, showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and Wnt signaling inhibition.
More Information Supplier PageMN-64 is a tankyrases inhibitor, showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and Wnt signaling inhibition.
More Information Supplier PageMN-64 is a tankyrases inhibitor, showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and Wnt signaling inhibition.
More Information Supplier PageSC66 is a AKT inhibitor in HepG2, HA22T/VGH, and PLC/PRF/5 cells (IC50: about 0.75 μg/ml, at 72 h).
More Information Supplier PageAPD597 is a GPR119 agonist, used in the treatment of type 2 diabetes.
More Information Supplier PageAPD597 is a GPR119 agonist, used in the treatment of type 2 diabetes.
More Information Supplier PageEslicarbazepine Acetate (Zebinix) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy.
More Information Supplier PageEslicarbazepine Acetate (Zebinix) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy.
More Information Supplier Page